Mechanism of Action of Therapeutic Plasma Exchange: Beyond Antibody Removal - A Systematic Review

Read full text Summarise with VIRAT
Authors: Hugo Fabre
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Therapeutic plasma exchange (TPE) is widely used across dozens of conditions, but the standard explanation — "we remove pathogenic substances from the blood" — doesn't hold up. In 2014, Reeves & Winters published a landmark paper posing 6 unanswered questions about how TPE actually works. Over a decade later, nobody has systematically attempted to answer them. This review aims to do that, while also integrating a large body of new evidence that has emerged since 2014. The 7 Research Questions: 1. Q1 — Antibody paradox: Why does TPE work when antibody titers don't correlate with disease severity (e.g., in myasthenia gravis, GBS, CIDP)? 2. Q2 — Extravascular paradox: How does TPE help when the pathological antibodies aren't even in the bloodstream (e.g., MS, NMO — targets behind the blood-brain barrier)? 3. Q3 — Immunomodulation existence: Does TPE genuinely alter the immune system beyond simple removal? 4. Q4 — Immunomodulation mechanism: If yes, what drives it — cytokine removal, antibody removal, direct blood-device contact, or replacement fluid effects? 5. Q5 — Cytokine debate: Is cytokine removal meaningful given their short half-lives and large volumes of distribution? 6. Q6 — Device-specific mechanisms: Are the mechanisms different for centrifugal TPE (cTPE) vs membrane-based TPE (mTPE)? 7. Q7 — Emerging frontiers: How do extracellular vesicles, intracellular signaling pathways (NF-κB, JAK/STAT, MAPK, NLRP3), and biological aging/parabiosis research inform the mechanistic framework? Review Structure (11 sections) 1. Introduction 2. Classical mechanism: removal of pathogenic substances 3. The antibody paradox (Q1) 4. The extravascular paradox (Q2) 5. Immunomodulatory effects of TPE (Q3/Q4) 6. Cytokine removal debate (Q5) 7. Complement modulation 8. Emerging frontiers — EVs, signaling, aging (Q7) 9. Device-specific mechanisms: cTPE vs mTPE (Q6) 10. Replacement fluid as a mechanistic variable 11. Synthesis and future directions Methodology - Full PRISMA 2020 compliance — pre-registered protocol on OSF, structured search, documented screening, PRISMA flow diagram - Search: 24 search lines across 5 databases (PubMed, MEDLINE, Embase, Web of Science, Scopus, Cochrane), plus forward/backward citation chaining and hand-searching of 3 key apheresis journals - Screening: Single reviewer (Hugo Fabre) with LLM-assisted triage - Quality assessment: Newcastle-Ottawa Scale, JBI, RoB 2 as appropriate per study design - Synthesis: Narrative (qualitative) — no meta-analysis due to heterogeneity of endpoints across studies Expected Outcomes / Novelty 1. First synthesis bridging classical and frontier evidence — connecting the Reeves & Winters 2014 framework with the Rony et al. 2025 EV/signaling/aging evidence 2. First systematic attempt to answer all 6 questions with a decade of accumulated new data 3. First focused review of cTPE vs mTPE mechanistic differences — an area with almost no dedicated literature, directly relevant to Terumo BCT's product portfolio 4. Integration of COVID-19 and CAR-T cytokine storm data as natural experiments illuminating the cytokine removal debate 5. Incorporation of biological aging literature — parabiosis and epigenetic clock studies as a new lens on TPE mechanisms Team - Hugo Fabre First author, sole reviewer, project lead (Terumo Blood and Cell Technologies, Global Medical Affairs) - Mickael Beraud Author, internal review - Melissa Kovac Medical librarian, search execution Current Status (as of March 2026) - Phase 1 (Protocol & Preparation): Complete — OSF registered, all search tools ready - Phase 2 (Search Execution): In progress — Q1 returned 1,858 records across 4 databases; all 21 priority papers obtained as full-text PDFs; Q2-Q10 pending from Melissa - Phase 6 (Data Extraction): Started early — extracting data from the 21 priority papers while waiting for remaining searches

Fields of Study & Subjects

Blood transfusion and management Monoclonal and Polyclonal Antibodies Research Peripheral Neuropathies and Disorders

Publication details

Publication date
1 January 2026
Language
EN
Document type
Preprint